CEN 109

Drug Profile

CEN 109

Alternative Names: 18F-EF5; CEN-109

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania; University of Turku
  • Class Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 17 Jun 2015 No recent reports of development identified - Phase-II for Cancer (Diagnosis) in USA (Parenteral)
  • 17 Jun 2015 No recent reports of development identified - Phase-I for Cancer (Diagnosis) in Finland (Parenteral)
  • 24 May 2011 Phase-II clinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top